久久精品国产精品亚洲色婷婷蜜芽_日韩欧美不卡一卡二卡3卡四卡202_這裏匯聚了国产精品精品自在线拍等最新內容_漂亮少妇按摩被中出中文字幕_亚洲欧美日韩精品永久在线_久久精品国产亚洲熟女_中文无码精品a∨在线_十九岁日本完整免费完整版观看_欧美三级电影视频_啊啊啊国产欧美日韩在线观看
Search
CN
About us
Our Company
Our Culture
Our History
Pipeline
Therapy
Product&Pipeline
Medicines
Health care
R&D
Complex Product and Platform
Innovative Medicines
Medical Devices
Technical Services(CDMO/CMO)
Partnering
Internationalization
R&D
One-stop service
Provide what you want
News
Press releases
Careers
Join us
Our Employees
Incentives
Opportunities
Investors
Investor contact
Contact us
CN
Home
About us
Our Company
Our Culture
Our History
Pipeline
Therapy
Product&Pipeline
Medicines
Health care
R&D
Complex Product and Platform
Innovative Medicines
Medical Devices
Technical Services(CDMO/CMO)
Partnering
Internationalization
R&D
One-stop service
Provide what you want
News
Press releases
Careers
Join us
Our Employees
Incentives
Opportunities
Investors
Investor contact
Contact us
Home
·
News
·
Press releases
·
Press releases
SCROLL DOWN
Press releases
Press releases
17
2022.11
Good News | CF PharmTech won the "Best Employer of Greater Suzhou" in 2022
9206
Share
On November 17, 2022, the 9th "Best Employers in Greater Suzhou" was officially announced by Suzhou Industrial Park Human Resources Development Co., LTD. With excellent human resource management pract
07
2022.11
Good news from CF PharmTech | The first domestic blockbuster product for the treatment of allergic rhinitis - Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (ShuFeiMin ?) was approved
8342
Share
Today, CF PharmTech, Inc. (hereinafter referred to as: "CF PharmTech") independently developed the heavy product ShuFeiMin? (National drug approval number: H20223778, general
25
2022.07
Announcement of the receipt of the listing notice to
CF PharmTech, Inc.
7680
Share
03
2020.07
CF PharmTech has completed F round of 360 million yuan equity investment to support rapid development of domestic high-end inhalation products.
7715
Share
CF PharmTech, Inc. (CF PharmTech, Inc., referred to as "CF PharmTech"), following the completion of the E round of 630 million financing in January, once again completed the F round of 360 million yuan financing, a total of nearly 1 billion financing with
About us
Our Company
Our Culture
Our History
Pipeline
Therapy
Product&Pipeline
Medicines
Health care
R&D
Complex Product and Platform
Innovative Medicines
Medical Devices
Technical Services(CDMO/CMO)
Partnering
Internationalization
R&D
One-stop service
Provide what you want
News
Press releases
Careers
Join us
Our Employees
Incentives
Opportunities
Investors
Investor contact
Contact us